Search - tctmd.com

Displaying 41 - 60 of 94

Sort: Relevancy | Date

News Opinion Editor's Corner

ISCHEMIA Questions? Some Answers From David Maron

Shelley Wood

December 09, 2019

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Marcus A. Banks

July 25, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Conference News SCCT 2019

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Yael L. Maxwell

July 15, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News

Yo-Yo Diets Linked to Poorer CV Health in Women

L.A. McKeown

March 07, 2019

News Daily News

Rising Number of CV-Related Maternal Deaths Spurs Need for #CardioObstetrics

Caitlin E. Cox

February 27, 2019

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

Advertisement

ISCHEMIA Questions? Some Answers From David Maron

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Yo-Yo Diets Linked to Poorer CV Health in Women

Rising Number of CV-Related Maternal Deaths Spurs Need for #CardioObstetrics

Top News in Endovascular Therapy: 2018

TCTMD’s Top 10 Most Popular Stories for November 2018

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content